FilingsTodayResmed
At a glance
Resmed reported 2025 revenue of $5.15B, up 9.8% from $4.69B in 2024. Over 4 years since 2021 ($3.2B), that is growth of about 12.6% a year. Operating margin was 32.7%, up from 28.3% in 2021. 2025 was the highest revenue year in this period.
In the last 12 months 5 insiders reported 0 open-market purchases and 32 sales ($22.4M). All of the sales were made under pre-arranged 10b5-1 trading plans. The largest was a sale of $2M by Chairman and CEO Michael J. Farrell on Nov 10, 2025.
Resmed filed 9 current reports (Form 8-K) in the last 12 months, most often for results of operations (5), officer or director change (3), other events (1) and auditor change (1). The latest officer or director change was reported on Aug 17, 2026.
3 of the 20 investors tracked here held Resmed at the last quarter end, worth $68.3M combined. It is the largest weight for Bridgewater Associates (0.1% of its portfolio), followed by National Pension Service (Korea) (0%). New this quarter: Renaissance Technologies. Added: Bridgewater Associates and National Pension Service (Korea).
Annual results
| Year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Net income | $474.5M | $779M | $898M | $1.02B | $1.4B |
| Diluted EPS | $3.24 | $5.30 | $6.09 | $6.92 | $9.51 |
| Dividend per share | $1.56 | $1.68 | $1.76 | $1.92 | $2.12 |
Fiscal year ends Jun 30 · incorporated in DE
Tracked investors holding (13F)
Weight is the share of each investor's portfolio, as of the quarter end.
Current reports (8-K, last 12 months)
Insider open-market trades (last 12 months)
Source: SEC EDGAR. How figures are combined